Navigation Links
ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
Date:12/3/2007

WASHINGTON and LA JOLLA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- ICx Technologies (Nasdaq: ICXT), a developer of advanced technology solutions for homeland security and force protection, announced today a research study with Merck & Co., Inc. and Fred Hutchinson Cancer Research Center of Seattle.

The purpose of the study is to test and refine a set of protocols for detecting and recovering circulating nucleic acids from blood -- a key early detector for cancer treatment - in order to support the development of an investigational cancer therapy. The study is being conducted by its La Jolla, Calif.-based Biosystems unit with participation by the Hutchinson Center.

"We have a history of aggressive research and development expertise and we're pleased to work with Merck," said ICx CEO Hans Kobler. "By applying the rapid and data-rich molecular diagnosis technology developed for security applications, ICx is hoping to aid the development of a diagnostic tool to assist in the evaluation of cancer therapies."

For more information, visit http://www.icxt.com.

About ICx Technologies(TM)

ICx develops advanced technologies for effective security solutions. ICx sensors detect and identify chemical, biological, radiological, nuclear and explosive (CBRNE) materials. ICx surveillance products discern people and objects invisible to human senses and conventional cameras. ICx software and systems connect, command and control these security devices, while its intelligence and special-operations experts provide the unique insight that drives the company's innovation. ICx has manufacturing and research facilities in the United States, Canada and Europe.

Statements contained in this press release that are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements, including statements relating to ICx Technologies' plans, objectives and expectations for future operations, are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by ICx Technologies. You should consider the risk factors described in ICx Technologies' prospectus as filed with the U.S. Securities and Exchange Commission on November 8, 2007, as well as other filings. ICx Technologies undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

All trademarks, registered trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE ICx Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... 17, 2017 , ... Wettstein Agencies, a Denver area firm ... throughout central Colorado, is joining local nonprofit Aurora Warms The Night to provide ... organization is committed to breaking the cycle of homelessness and poverty affecting a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC (PER®) ... speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 ... Phil Talamo, said, “We are delighted to have Sandra Lee join us as ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader in ... agreement as part of a long-term extension of their media partnership. The partnership, which ... some of the sport’s premier events exclusively on FloWrestling.com as well as usage of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research and Markets has announced the addition of the "Active ... (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, ... offering. ... global active pharmaceutical ingredients market is expected to reach USD 213.97 ... a CAGR of 6.3% from 2016 to 2021. ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ... tests and pathology services for evaluating risks of cancer, ... January 13, 2017 from the NASDAQ Listing Qualifications notifying ... requirement of the NASDAQ Stock Market to maintain a ... The letter noted that for the last 10 ...
Breaking Medicine Technology: